May increase the clearance of paracetamol/acetaminophen, diazepam and morphine
What the Evidence Actually Supports Its worth being precise about the state of evidence, because the gap between preclinical research and proven human clinical outcomes is significant in this area: Strong preclinical evidence: Hundreds of cell culture and animal studies demonstrate GHK-Cus biological activity across multiple pathways Moderate clinical evidence for topical applications: Several controlled human trials support skin benefits of topical GHK-Cu formulations Limited human evidence for systemic effects: The more dramatic claims tissue regeneration, gene expression reset, anti-aging effects throughout the body are largely supported by in vitro and animal data without the controlled human trials required to confirm efficacy and safety The scientific communitys interest in GHK-Cu is well-founded
Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis
Synthetic delta-sleep-inducing peptide improves sleep in insomniacs Schneider-Helmert D, Schoenenberger GA The Lancet (1981) This pioneering clinical study examined DSIP's effects in patients with chronic primary insomnia, representing one of the first controlled human trials of the peptide for sleep disorders
Contraindications: allergy to ingredients, certain liver/kidney conditions, or B12 sensitivity.